

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
3 June 2004 (03.06.2004)

PCT

(10) International Publication Number
WO 2004/046160 A3

(51) International Patent Classification⁷: **A61K 31/7088, C07H 21/00**

(21) International Application Number: **PCT/DK2003/000788**

(22) International Filing Date: **18 November 2003 (18.11.2003)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
PA 2002 01774 18 November 2002 (18.11.2002) DK
PA 2003 01540 20 October 2003 (20.10.2003) DK

(71) Applicant (for all designated States except US): **SANTARIS PHARMA A/S [DK/DK]; Bøge Allé 3, DK-2970 Hørsholm (DK).**

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CHRISTENSEN, Signe, M. [DK/DK]; Gammeltoftsgade 24, 3. tv., DK-2200 Copenhagen N (DK). MIKKELSEN, Nikolaj, Dam [DK/DK]; Stenløsevej 52, DK-2700 Brønshøj (DK). FRIEDEN, Miriam [DK/DK]; Rådmandssgade 15. 3. th., DK-Copenhagen N (DK). HANSEN, Henrik, Frydenlund [DK/DK]; Tårnvej 33 A, st., DK-2610 Rødovre (DK). KOCH, Troels [DK/DK]; Funkiavej 47, DK-2300 Copenhagen S. (DK). PEDERSEN, Daniel, Sejer [DK/GB]; Darwin College, Silver Street, Cambridge CB3 9EU (GB). ROSENBOHM, Christoph [DK/DK]; Kirsebærlunden 25, 3460 Birkerød (DK). THRUE, Charlotte, Albæk [DK/DK]; Kronprinsessegade 80 st., 1306 København K (DK). WESTERGAARD, Majken [DK/DK]; Ellebakken 5, DK-3460 Birkerød (DK).**

(81) Designated States (national): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, EG, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report

(88) Date of publication of the international search report: **21 October 2004**

(48) Date of publication of this corrected version: **7 July 2005**

(15) Information about Correction:
see PCT Gazette No. 27/2005 of 7 July 2005, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **AMINO-LNA, THIO-LNA AND ALPHA-L-OXY-LN**

(57) Abstract: A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.

WO 2004/046160 A3